Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 November 2022 | Story Anthony Mthembu | Photo Barend Nagel
Siphilangenkosi Dlamini
Siphilangenkosi Dlamini – selected by Inside Education and the NYDA as one of South Africa’s 100 Shining Stars for 2022.

Siphilangenkosi Dlamini, a fourth-year Governance and Political Transformation student at the University of the Free State (UFS), has been selected as one of South Africa’s 100 Shining Stars for 2022 by Inside Education, in partnership with the National Youth Development Agency (NYDA). 

“I was more surprised than anything, but also very honoured,” he said. Dlamini, who made it into the Civil Society and Youth category, was chosen from a pool of 800 applicants for his remarkable work with the Help a Student initiative, and his services as the former secretary of the Southern Africa Scout Youth Forum. Although he could not attend the award ceremony held in Johannesburg on 20 October 2022 in person, Dlamini did receive a certificate. “What we do a lot of the time isn’t for recognition and it’s not necessarily for awards; but getting recognised motivates and assures me that the work we are doing has an impact,” he expressed.

The Help a Student Initiative

In the early stages of the COVID-19 pandemic, Dlamini recognised a rise in food insecurity among his fellow students. This set him on a path to source funding for the establishment of the project. 

The Help a Student initiative aimed to curb food insecurity through the provision of food parcels to UFS students who were in need. The project, which ran from 2020 until early 2021, managed to distribute food parcels to nearly 250 students per month. The initiative did not only assist students who were on campus. The selected applicants who were at home or off campus also received digital food vouchers, which allowed for the purchasing of food items at Pick n Pay and/or Shoprite.

“Food security is something that I am passionate about. I grew up in a community where it was a massive issue.

However, in the past I was not empowered enough to know how to solve it. Therefore, when the opportunity presented itself to do something about it, I took it with both hands,” Dlamini expressed.

Although the recognition was not expected, Dlamini maintains that such platforms are imperative, as “they demonstrate that young people are doing something to improve the country in the different capacities they are in”.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept